03:11 AM EDT, 10/25/2026 (MT Newswires) -- AstraZeneca (AZN.L, AZN.ST) reported that its late-stage study for its combination treatment for patients with muscle-invasive bladder cancer showed improvement in event-free survival. The British drugmaker said its Volga phase 3 trial, which reviewed Imfinzi with neoadjuvant enfortumab vedotin, reduced the risk of disease progression, recurrence, death, or not undergoing surgery by 49%, according to an Oct. 24 release. AstraZeneca added that the treatment combo lowered the risk of death by 42%, with its safety and tolerability being consistent.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.